Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.

Coeptis paid $570,000 in cash to Deverra and provided four million shares from its common stock.

The deal allows Coeptis to strengthen its existing SNAP-CAR and GEAR technologies with two investigational new drug applications and two assets of Deverra that are currently undergoing Phase I clinical study.

The trial is investigating the infusion of unmodified natural killer (NK) cell therapy DVX201, produced from pooled donor CD34+ cells to treat haematologic malignancies and viral infections.

Coeptis will also add an allogeneic cellular immunotherapy platform that is being developed for producing and delivering off-the-shelf (without HLA matching) on-demand cell therapies.

Coeptis will also infuse clinical stage-ready allogeneic technologies into its pipeline assets. These will help in developing allogeneic-engineered NK and MAC cell therapies.

Coeptis Therapeutics president and CEO Dave Mehalick stated: “Finalising this transaction represents a pivotal transition of Coeptis into a clinical-stage company with novel, synergistic and differentiated cell therapy pipeline candidates.

“As we move forward, I am excited to work with Colleen Delaney MD, a visionary scientist whose career has been dedicated to researching and advancing all aspects of cell therapy product development.

“A true leader in the field, Colleen's experience and leadership will be invaluable as we progress our expanded pipeline towards our ultimate goal of bringing improved treatments to patients in need.”